Jose Morfin, MD
Nephrology · Sacramento, CANPI 1376528877
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $753,927 of the $1,032,547 with a category attached, or 73.0%. 15 manufacturers reported payments, led by AstraZeneca at 42.0% of the total. Reporting peaked in 2021 at $228,994 and has fallen 71.7% since, to $64,754 in 2025. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,140 payments — averaging $905.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$434K
- Nxstage Medical, Inc.$218K
- Aurinia Pharma U.S., Inc.$126K
- Amgen$91K
- Ardelyx, Inc.$67K
- Bayer$32K
- plus $64K from 9 others
What the payments were for
- Consulting fees$145,95114%
- Speaking & faculty fees$753,92773%
- Travel & lodging$108,75911%
- Food & beverage$23,8842%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 516 | $433,706 |
| Nxstage Medical, Inc. | 195 | $218,249 |
| Aurinia Pharma U.S., Inc. | 172 | $125,597 |
| Amgen | 115 | $91,215 |
| Ardelyx, Inc. | 64 | $67,479 |
| Bayer | 30 | $31,829 |
| GSK | 20 | $29,380 |
| Vifor Pharma, Inc. | 16 | $17,781 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $10,455 |
| Fresenius USA Marketing, Inc. | 1 | $2,500 |
| Otsuka America Pharmaceutical, Inc. | 1 | $1,845 |
| Shield Therapeutics Inc | 1 | $1,700 |
| Johnson & Johnson | 2 | $750 |
| Novartis | 1 | $49 |
| Outset Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$402,714
- NXSTAGE SYSTEM ONE$144,592
- LUPKYNIS$122,595
- Tavneos$90,023
- System One$71,459
- XPHOZAH 30 MG$67,026
- Kerendia$31,287
- FARXIGA$23,274
- JESDUVROQ$12,177
- BENLYSTA$7,918
- Korsuva$5,137
- Veltassa$4,433
- JYNARQUE$2,050
- ACCRUFER$1,700
- INVOKANA$750
- PUREFLOW SL$112
How this compares
$1,032,547 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LupkynisVoclosporin | 11 | $160,503 |
| VelphoroSucroferric Oxyhydroxide | 23 | $56,523 |
| XphozahTenapanor Hcl | 11 | $38,288 |
| KerendiaFinerenone | 31 | $27,222 |
| LokelmaSodium Zirconium Cyclosilicate | 41 | $24,725 |
| JardianceEmpagliflozin | 33 | $22,147 |
| Sevelamer Carbonate | 86 | $16,014 |
| FarxigaDapagliflozin Propanediol | 16 | $11,731 |
| Midodrine Hcl | 21 | $3,725 |
| Calcium Acetate | 28 | $3,587 |
| Clonidine | 20 | $3,298 |
| Bumetanide | 19 | $962 |
| Losartan Potassium | 77 | $572 |
| Hydralazine Hcl | 20 | $446 |
| Carvedilol | 57 | $389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aurinia Pharma U.S., Inc.Lupkynis | $125,597 | $160,50311 claims |
| Fresenius USA Marketing, Inc.Velphoro | $2,500 | $56,52323 claims |
| AstraZenecaLokelma, Farxiga | $433,706 | $36,45557 claims |
| BayerKerendia | $31,829 | $27,22231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Sacramento
- Naveen AtraySacramento$51K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
- Suphamai BunnapradistLos Angeles$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.